Nurix Therapeutics shows strong BTK degrader data and key pharma ties, with risks but solid long-term potential. Find out why ...

Schools across the state are eliminating DEI offices, restructuring programs, and implementing new course requirements.

Full data from Phase 3 TRANSCEND study underscore potential efficacy of setmelanotide, including with prior use or concomitant use of GLP-1s - BOSTON, July 12, 2025 (GLOBE NEWSWIRE) -- Rhythm ...